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Aim: To investigate the anticancer efficiency of the xenogeneic vaccine in different tumor models and to assess the possibility whe ther 
level of antibodies (Ab) specific for vaccine’s proteins can be used as an indication for its use. Methods: Mice with Lewis lung carci-
noma (LLC), Ehrlich carcinoma (EC) or Sarcoma 37 (S37) were immunized with a xenogeneic anticancer vaccine based on chicken 
embryo proteins (CEP) and its anticancer activity was examined. The level of specific Ab in the blood serum of non-immunized tumor-
bearing mice was studied by ELISA. Results: CEP application statically significantly inhibited the growth of LLC (the index of tumor 
growth inhibition was 42.10–53.13% depending on the day of tumor growth); vaccinated mice with EC showed significant tumor growth 
inhibition and life prolongation by 34.48%. Among mice with S37, there was noticed no antitumor effect. The number of tumor-
bearing non-immunized mice which have had pre-existing CEP-specific Ab did not differ depending on the tumor model. The level 
of CEP-specific Ab among mice with LLC and EC increased with the growth of the tumor volume, but it decreased among mice be-
aring S37. Probably, the low level of CEP-specific Ab alongside huge tumor burden shows it is futile to apply the CEP-based vaccine. 
Conclusion: Different tumor strains vary in their susceptibility to CEP-based vaccine. Probably, the low level of CEP-specific Ab when 
a tumor burden is huge shows it is futile to apply the CEP-based vaccine.
Key Words: xenogeneic anticancer vaccine, chicken embryo proteins anticancer activity, Lewis lung carcinoma, Ehrlich carcinoma, 
Sarcoma 37, CEP-specific antibodies.
The construction of xenogeneic anticancer 
vaccines (AV) is a comparatively new but fairly pro-
mising field in cancer biotherapy. The development 
of AV based on xenogeneic analogues of tumor associ-
ated antigens (TAA) was brought about by two facts: 
1) tumor antigens are generally products of expres-
sion of unmutated patient genes which are tolerated 
by the body’s immune system; 2) the use of homologi-
cal xenogeneic antigens can overcome immunological 
tolerance to these proteins [1, 2].
Now a number of researches showed the abi-
lity of xenogeneic analogues to overcome immu-
nological tolerance to tumor antigens or proteins 
connected to carcinogenesis [3–6]. The antitumor 
efficiency of some xenogeneic vaccines was proved 
by a number of experimental [2, 3, 5–8] and clinical 
researches [9–11]. On the other hand, indications for 
use of xenogeneic AV are not evident enough. In gene-
ral, it is not a problem in a case of those vaccines which 
are based on the limited number of antigens: the tu-
mor’s expression of these antigens or proteins involved 
in carcinogenesis is an indication for use of a relevant 
vaccine. Nevertheless, the identification of tumor an-
tigenic spectrum by every patient requires much time 
and expense. The problem is more acute for polyvalent 
vaccines or vaccines based on tissue homogenates 
and extracts. That is to say, it is urgent to find simple 
and quick methods to predict the expedience of xeno-
geneic vaccine use. Xenogeneic vaccines certainly 
cannot pretend to be “universal” vaccine, therefore 
there is a still open question how to assess “the ap-
plicability spectrum” of every xenogeneic vaccine, 
i.e. to choose the factors of their expedience for use.
Tumor and embryonic cells are believed to have 
common features: embryonic cells express antigens 
which are similar to oncofetal antigens of tumor 
cells [12, 13]. Moreover, it is known from the literature 
that the embryo cells of the chicken express proteins, 
which share homology with the human and mouse tumor 
antigens [3, 5, 14–16]. The literature tells us about suc-
cessful application of some proteins or genes of chicken 
origin as a xenogeneic AV [3, 5, 8]. So, the development 
of a xenogeneic vaccine based on chicken embryo pro-
teins (CEP) looks promising. In R.E. Kavetsky Institute 
of Experimental Pathology, Oncology and Radiobiology 
(IEPOR) of NAS of Ukraine, the work is proceeding with 
elaboration of the xenogeneic AV based on CEP.
The aim of this particular research project has 
been to study the anticancer efficiency of the xeno-
geneic vaccine based on CEP on different models 
of  cancerous growth and assess the possibility to apply 
the level of CEP-specific antibodies (Ab) as an indica-
tion for use of the vaccine.
MATERIALS AND METHODS
The study has been carried out on male C57Bl/6 and 
Balb/c mice 2–2.5 months old weighting 19–20 g, 
bred in the vivarium of R.E. Kavetsky IEPOR of NAS 
of Ukraine. The use and care of experimental animals 
have been performed in accordance with standard 
international rules on biologic ethics and was ap-
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proved by Institutional Animal Care and Use Commit-
tee [17, 18].
Anticancer efficacy of CEP was examined when 
vaccination was applied after tumor transplanta-
tion — so called therapeutic vaccination. Three dif-
ferent tumor strains were used: Lewis lung carcinoma 
(LLC), Ehrlich carcinoma (EC) and Sarcoma 37 (S37). 
To establish tumors, cancer cells suspension was in-
jected i.m. in the right hind leg at a dose of 4•105 cells/
mouse (LLC, EC) or 5•105 cells/mouse (S37). Unvacci-
nated mice with the tumor of relevant strain are referred 
as a control.
LLC bearing mice were immunized on days 1st, 8th 
and 15th after tumor injection.
EC bearing mice were immunized on days 2nd, 5th, 
and 8th after tumor injection.
Vaccination of S37 bearing mice has been per-
formed by three schemata: at 1st, 8th, 15th days 
(scheme 1, group 1), at 2nd, 5th, and 8th days (sheme 2, 
group 2) and at 7th, 14th, 28th days after tumor cell 
transplantation (scheme 3, group 3).
In all the cases, immunizations were performed 
s.c. with 0.3 ml of CEP solution per mouse (protein 
concentration 0.3 mg/ml).
Mouse sera were collected on days 7th, 14th, 21st 
and 28th after tumor transplantation. Sera were frozen 
and stored at −20 °С. By an enzyme-linked immu-
nosorbent assay (ELISA) sera were tested for CEP-
specific or TAA specific Ab as described in [19]. Briefly, 
the CEP or TAA at 0.3 mg/mL were incubated for 
24 h at 4  °C on 96-cells microtiter plates. Nonspecific 
binding was blocked with 3% BSA for 1 h at 37 °C. Sera 
were added at dilution 1:20 (sera dilution was se-
lected in preliminary tests). Bound Ab were revealed 
using goat antimouse IgG and IgM peroxidase conju-
gate (Dako) and o-phenyldiamine/H2O2 substrates. 
Plates were read at 492 nm in an MicroELISA (Stat 
Fax 2100, USA) auto-reader. The negative control 
consisted of naїve mouse sera in the same dilution. 
The results are presented as factor F [20]: 
F = ODexperiment/ODcontrol, (1)
where ODexperiment stand for optical density of cells 
with serum of tumor-bearing mice, ODcontrol stand 
for optical density of cells with naïve mice serum. 
The F value exceed 2 was taken as indication of Ab-
positive serum.
CEP was prepared as follows [21]. Briefly, 7 days 
chicken embryos were rinsed two times in cold NaCl 
0.9% solution, homogenized and then extracted 
with NaCl 0.9% solution, containing 0.1% EDTA, 
for 60 min at 4 °C by agitation. Following extraction, 
chicken embrio tissue was removed by centrifuga-
tion at 1.500 g for 30 min. The resulting supernatant 
was collected and frozen at −20 °C. TAA of LLC, 
EC and S37 were prepared by three consecutive cycles 
of freezing and melting of cells suspension. Following 
the last melting, cell debris was removed by centrifuga-
tion at 1.500 g for 30 min. The resulting supernatants 
were collected and frozen at −20 °C. Concentration 
of proteins in the extracts was measured by Greenberg 
and Craddock assay [22]. The same extracts were 
used in all the experiments, described in the article.
Tumor dimensions were measured with calipers, 
and tumor volumes were calculated according 
to the formula: 
tumor volume = 4/3π • width2 • length • 0,5 (2)
Index of tumor growth inhibition (ITGI) was calcu-
lated according to the formula:
 Vcontrol mice — Vimmunized miceITGI = ——————————————————  100%, (3)
 Vcontrol mice
where Vcontrol mice and Vimmunized mice stand for mean 
tumor volume in control unimmunized and immunized 
mice respectively [23].
Index of life span prolongation (ILSP) was calcu-
lated as following:
 survival timeimmunized mice — survival timecontrol miceILSP = —————————————————————————————————————  100%, (4)
 survival timecontrol mice
where survival timeimmunized mice and survival timecontrol mice 
stand for survival time (days) in immunized and control 
groups respectively [23].
Metastasis inhibition index (MII) was calculated 
as following:
 Аc • Вc — Аi • ВiMІІ = —————————————  100%, (5)
 Аc • Вc
Аc and Аi stand for number of mice bearing lung 
metastases in groups of control and immunized mice 
respectively. Вc and Вi stand for mean number of lung 
metastases in groups of control and immunized mice 
respectively [24].
Pearson correlation coefficient (r) was adjusted for 
sample size [25].
RESULTS
Study into anticancer activity of the CEP-based 
vaccine on the model of LLC. According to obtained 
results, tumors formed on 9–11th day after the LLC cells 
injection in six out of ten (60%) animals of the control 
and treatment groups. The tumor volume (Fig. 1) in im-
munized animals for the whole period of observation 
was smaller compared to the results of control mice 
(р < 0.05 before day 20 and р < 0.1 since 25th until 28th 
day of tumor growth).
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Fig. 1. The tumor volume of vaccinated with CEP-based vaccine 
and control mice bearing LLC
On the 28th day after the LLC implantation, the ani-
mals were euthanized and metastases were assessed 
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(Table 1). According to the obtained data, the mean 
volume of metastases in the group CEP was 2.2 times 
smaller comparing to the control group. The mean num-
ber of metastases per mouse in the group tended to de-
crease among the immunized mice (0.05 < р < 0.1 com-
paring to the control group). MII for the immunized 
animals was 77.56% and 66.35% — per group in general 
and per animals bearing metastases respectively.
Table 1. Metastases in vaccinated and unvaccinated mice bearing LLC
Group Metastases rate, % (sample size/mts+)
Metastases 
volume, mm3
Metastases number
per mouse 
bearing 
 metastases
per mouse 
in a group
Control 85.71 ± 12.37 (5/5) 10.11 ± 5.39 10.4 ± 3.4 10.4 ± 3.4
CEP 66.67 ± 19.25 (6/4) 4.61 ± 3.98 4.5 ± 1.97 3.0 ± 1.57*
Notes: * р < 0.1 comparing to the control group.
Hence, the AV based on CEP had a significant an-
titumor and some antimetastatic effect.
Study into anticancer activity of the CEP-based 
vaccine on the model of EC. An anticancer effect 
of the CEP-based vaccine was evident in the model 
of EC. Although tumors formed in every unvaccinated 
and vaccinated animal on the 5–7th day after the trans-
plantation (Table 2), the immunized mice showed 
significant inhibition of tumor growth (Fig. 2).
Table 2. The latent period of tumor formation and the survival time for 
vaccinated with the CEP-based vaccine and control mice bearing EC
Group 
(sample size)
Latent period of tu-
mor formation (days)
Survival time 
(days)
Median survival 
(days)
Control (14) 5.50 ± 0.34 43.77 ± 2.35 44.0
CEP (14) 6.36 ± 0.78 58.86 ± 4.09* 55.0
Notes: *p < 0.05 comparing to control group.
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Fig. 2. The tumor volume of vaccinated with CEP-based vaccine 
and control mice bearing EC
Significant difference (p < 0.05) in tumor volu me 
between unvaccinated and vaccinated animals was evi-
dent since the 13th day, i.e. after the end of vaccination. 
In particular, on the 13th and 16th day of tumor growth ITGI 
in the group of vaccinated mice was 50.57 and 50.74% 
respectively. Later the diffe rence is gradually getting 
smaller (46.11 and 43.27% on the 20th and 23rd day of tu-
mor growth respectively), but it stays higher than by 20% 
until the 30th day, when animals in the control group start 
dying. As a result of tumor growth inhibition, survival time 
in the group of vaccinated mice increased (р < 0.05): the 
ILSP in the CEP group reached 34.48%.
To sum up, using CEP on the model EC inhibited 
tumor growth, and, as a result, significantly lengthened 
the life span of tumor-bearing animals.
Study into anticancer activity the CEP-based 
vaccine on the model of S37. The anticancer ef-
fect of CEP in case of S37-bearing mice was inves-
tigated applying different schemata of vaccination; 
however, there was no significant difference between 
groups of vaccinated and unvaccinated animals. So, 
Table 3 illustrates the data about the latent period 
of tumor forming and the survival time of immunized 
animals under different schemata: none of indices 
between the groups differ significantly.
Table 3. The latent period of tumor formation and the survival time for vac-
cinated with the CEP-based vaccine and control mice bearing S37
Group 
(sample size)
Latent period of tu-
mor formation (days)
Survival time 
(days)
Median survival 
(days)
Control (15) 6.93 ± 0.29 45.67 ± 3.79 43.0
CEP № 1 (6) 6.67 ± 0.37 42.50 ± 3.81 41.0
CEP № 2 (7) 7.14 ± 0.44 34.57 ± 2.05 33.0
CEP № 3 (15) 7.00 ± 0.20 41.93 ± 2.12 42.0
The tumor volume of unimmunized and immunized 
mice bearing S37 did not differ significantly, though 
different schemata of vaccination were applied (Fig. 3). 
In other words, immunization did not affect signifi-
cantly any indices of tumor growth; so we considered 
S37 were resistant to the CEP-based vaccine.
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Fig. 3. The tumor volume of vaccinated with CEP-based vaccine 
and control mice bearing S37
As it appeared, different tumor strains differ 
in susceptibility to the CEP-based vaccine. The ques-
tion arises whether there are any criteria according 
to which it would be possible to predict the efficiency 
of the CEP-based vaccine.
The evaluation of CEP-specific Ab in blood 
serum of tumor-bearing mice as an indication for 
use of the anticancer xenogeneic vaccine based 
on CEP. The blood serum from unvaccinated mice 
bearing tumors (LLC, EC and S37) on different days 
after tumor cells injections (on the 7th, 14th, 21st and 
28th day) was taken and checked for its ability to react 
with its own tumor antigens (TAA) and CEP and the cor-
relation coefficient between the level of CEP-specific 
or TAA-specific Ab and tumor volume was calculated.
Table 4 compares the portion of animals bearing 
different tumors whose blood serum was positive for 
TAA- and CEP-specific Ab. It is obvious that the num-
ber of animals in whose blood serum CEP- and TAA-
specific Ab were detected was approximately equal. 
However, the portion of S37-bearing mice whose blood 
serum was positive for CEP-specific Ab was slightly 
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lower than that (0.05 < р < 0.1) whose serum was 
positive for their own TAA.
Table 4. The portion of blood serum samples positive for TAA- and CEP-
specific Ab depending on tumor strains
Tumor 
strain
Portion of blood serum samples positive for
TAA-specific Ab, % (n) CEP-specific Ab, % (n)
S37 91.67 ± 5.64 (22 out of 24) 70.83 ± 9.28 (17 out of 24)*
EC 81.82 ± 8.42 (18 out of 22) 77.27 ± 9.17 (17 out of 22)
LLC 83.33 ± 7.61 (20 out of 24) 79.17 ± 8.29 (19 out of 24)
Notes: *0.05 < р < 0.1 comparing to a portion of blood serum samples which 
are positive for TAA-specific Ab
The level of TAA-specific Ab in blood serum of tu-
mor-bearing mice was almost the same and did not 
depend on the tumor strain or the day after tumor 
transplantation (Fig. 4, a). As a result, there was not 
found any correlation between the level of TAA-specific 
Ab and tumor volume (see Table 5, where correlation 
coefficients are presented).
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Fig. 4. The level of TAA- (a) or CEP-specific (b) Ab in blood serum 
of mice bearing different tumors, depending on the term after 
the tumor cells injection
Table 5. Pearson correlation coefficient (r) between the tumor volume 
and the level of TAA- or CEP-specific Ab depending on the tumor strain
Tumor strain
Correlation coefficient between tumor volume 
and level of
TAA-specific Ab CEP-specific Ab
S37 0.04 −0.48**
EC −0.09 0.67*
LLC 0.26 0.42**
Notes: *р < 0.05; **р < 0.07.
The level of CEP-specific Ab varied and differed more 
significantly (Fig. 4, b). For example, mice with S37 showed 
the highest level of CEP-specific Ab on the 7th day after 
tumor transplantation, which was decreasing gradually 
and significantly (p < 0.05  comparing to the 7th day) until 
the 28th day of the experiment. In contrast, EC-bearing 
mice had the lowest level of CEP-specific Ab on the 7th day, 
but it statistically significantly grew until the 28th day of tu-
mor growth. In the group of LLC-bearing mice, the level 
of CEP-specific Ab gradually increased, but there was 
no statistically significant difference between indices 
on different days of tumor growth.
So, there was a strong, but multidirectional correla-
tion between the level of CEP-specific Ab and tumor 
volume (see Table 5): the correlation was positive 
for mice bearing LLC and EC (r = 0.42; р < 0.07 and 
r = 0.67; р < 0.05 respectively), but it was negative for 
mice bearing S37 (r = −0.48; р < 0.07).
So, the detection of CEP-specific Ab in blood 
serum per se cannot be applied as an indication for 
use of the CEP-based vaccine, as long as the same 
portion of mice bearing resistant and nonresistant 
tumor strains were positive for it. However, if the 
level of CEP-specific Ab is low, but a tumor burden 
is huge or the level of Ab is decreasing while a tumor 
is  growing, it possibly can indicate the tumor is resis-
tant to the CEP-based vaccine.
DISCUSSION
According to the results, the antitumor efficiency 
of CEP was evident in the case of two out of three tumor 
strains used in the study. The high anticancer efficiency 
of CEP was shown on two models of carcinoma: EC (the 
tumor came into being as spontaneous breast cancer 
[26]) and LLC (the tumor came into being as lung cancer 
[26]); however, sarcoma (S37 started to exist as a breast 
tumor, but through many transplantations it turned into un-
differentiated polymorphous cell sarcoma [26]) turned out 
to be resistant to the CEP-based vaccine both at different 
therapeutic schemata of vaccination and at prophylac-
tic — before tumor was transplanted — one (the data are 
not shown). Since the tumor models, used in the study, 
differ in histogenesis, we can assume that the anticancer 
efficiency of the CEP-based vaccine depends on this 
factor. However, it is impossible to prove or disprove this 
assumption in the scope of this work, because the number 
of model tumors (only 3) is not enough for this.
The fact should be pointed up that both “sensitive” 
to the vaccine tumors (LLC and EC) are undifferenti-
ated or poorly differentiated carcinomata. The low 
level of tumor differentiation generally is associated 
with a worse prognosis [27]. It can be assumed that 
the application of the vaccine based on CEP, probably, 
can improve the results of treatment in case of un- and 
poorly differentiated carcinomata.
On the other hand, the obtained results — diffe-
rent anticancer efficiency in the case of different tumor 
models — once more point to the necessity to find a reli-
able indication for use of the CEP-based vaccine. Most 
prognostic and diagnostic markers that are used now 
in clinical and laboratorial practice are based on  detecting 
in serum specific proteins, so-called oncomarkers 
or Ab specific to them. Now a growing body of literature 
points to the importance to detect in serum oncomar-
kers specific Ab as a more sensitive method [28–30]. 
The advantage of the latter is due to several factors. 
Particularly, the levels of oncomarkers sufficient for de-
tection in serum appear at relatively later stages of tumor 
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growth when it already has clinical signs. Meanwhile, 
Ab specific to these oncomarkers can be detected 
at earlier stages of tumor growth, sometimes even before 
clinical signs of a tumor [31, 32]. Therefore, we decided 
to check whether the presence of CEP-specific Ab can 
serve as an indication for use of the vaccine.
It was shown that some portion of mice bearing 
resistant or nonresistant tumor strains was positive for 
CEP-specific Ab: 70.73 ± 9.28% of S37 bearing mice 
(considered as resistant tumor) and 77.27 ± 9.17% and 
79.17 ± 8.29% of EC and LLC bearing mice respectively 
expressed CEP-specific Ab in their blood serum. So, 
CEP-specific Ab in the blood serum per se cannot 
be applied as an indication for use of the CEP-based 
xenogeneic vaccine. Changes in CEP-specific Ab le-
vels were more informative. In the case of S37 bearing 
mice the level of CEP-specific Ab was decreasing while 
tumor was growing (correlation coefficient was −0.48). 
 Pro bably, CEP-specific Ab have formed circulating 
immune complexes, so they could not be detected 
in  ELISA, or the level of CEP-specific Ab decreased 
during the formation of immune response to the tumor 
as having lower affinity to TAA of S37. On the contrary, 
in the case of “sensitive” LLC or EC the level of CEP-
specific Ab was constantly increasing. Considering 
that, in the process of immune response formation 
the number of Ab with higher affinity is growing (other-
wise known as affinity maturation [33]), we may assume 
that CEP more resemble EC’s or LCC’s TAA (or contain 
more proteins which share homology with these tumor 
antigens), than that of S37. That is why immuniza-
tion with CEP has no effect on S37. So, the low level 
of CEP-specific Ab together with a huge tumor burden 
may indicate that tumor is resistant to the CEP-based 
AV therapy.
In conclusion, the application of the CEP-based 
vaccine to animals with LLC and EC had anticancer and 
antimetastatic effects: statistically significant tumor 
growth inhibition (both models), statistically signifi-
cant lengthening of survival time by 34.48% (EC) and 
the inhibition of metastasizing of LLC — Index of me-
tastases inhibition reached 77.56%. The CEP-based 
vaccine did not have any anticancer effect in the case 
of S37. Detection of CEP-specific Ab in a blood serum 
per se cannot be applied as an indication for use 
of the CEP-based vaccine. However, the low level 
of CEP specific Ab when tumor burden is huge points 
to the unfeasibility of vaccine based on CEP.
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